このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Hikma Pharmaceuticals バランスシートの健全性
財務 の健全性 基準チェック /46
Hikma Pharmaceuticalsの総株主資本は$2.2B 、総負債は$1.1Bで、負債比率は50.9%となります。総資産と総負債はそれぞれ$4.7Bと$2.5Bです。 Hikma Pharmaceuticalsの EBIT は$619.0Mで、利息カバレッジ比率9.4です。現金および短期投資は$229.0Mです。
主要情報
50.9%
負債資本比率
US$1.13b
負債
| インタレスト・カバレッジ・レシオ | 9.4x |
| 現金 | US$229.00m |
| エクイティ | US$2.21b |
| 負債合計 | US$2.47b |
| 総資産 | US$4.68b |
財務の健全性に関する最新情報
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Recent updates
Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Sep 01Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price
Jun 02Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Feb 21Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 24These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well
Jun 06Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Feb 26Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price
Dec 01Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?
Nov 11Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?
Sep 02Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Aug 09Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate
May 21Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly
May 03It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year
Apr 16How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?
Apr 13Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend
Mar 14Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 28I Ran A Stock Scan For Earnings Growth And Hikma Pharmaceuticals (LON:HIK) Passed With Ease
Feb 22Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 23% Undervaluation?
Feb 03財務状況分析
短期負債: HIKの 短期資産 ( $2.1B ) が 短期負債 ( $1.3B ) を超えています。
長期負債: HIKの短期資産 ( $2.1B ) が 長期負債 ( $1.1B ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: HIKの 純負債対資本比率 ( 40.6% ) は 高い と見なされます。
負債の削減: HIKの負債対資本比率は、過去 5 年間で36.1%から50.9%に増加しました。
債務返済能力: HIKの負債は 営業キャッシュフロー によって 十分にカバー されています ( 54% )。
インタレストカバレッジ: HIKの負債に対する 利息支払い は EBIT ( 9.4 x coverage) によって 十分にカバーされています。